Antidepressants at low dose are commonly prescribed for the management of chronic low back pain and their use is recommended in international clinical guidelines. However, there is no evidence for their efficacy.
L ow back pain (LBP) is the largest contributor to disability worldwide. 1 Although there are a range of treatments available for LBP, the efficacy of these therapies are limited. 2 Antidepressants are a commonly prescribed treatment for LBP in clinical practice. 3 Typically, higher doses of antidepressants are used to treat depression, whereas low doses are prescribed for chronic pain, with the analgesic effects of the drug occurring independent of depression. 4 The use of antidepressants is rapidly increasing, with an increase in prescriptions of 3.9 million (6.8%) over 12 months in the United Kingdom 5 and 29% of these reported to be off label (unapproved indication). 6 This is despite the lack of evidence from systematic reviews 7 and conflicting recommendations in clinical guidelines. 8 A review of national and international guidelines has highlighted that not only do recommendations for antidepressant treatment for LBP vary substantially, but 7 of 14 guidelines recommend their use, with none indicating whether they should be prescribed in high or low doses. 8 Two treatment guidelines published in 2016 to 2017 provide further conflicting recommendations, 1 stating that while tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors are not recommended, duloxetine hydrochloride should be considered as a second-line therapy, 9 whereas the other did not recommend the use of any class of antidepressant for chronic LBP. 10 A number of systematic reviews, including our Cochrane systematic review, 7 have concluded that there is no clear evidence that antidepressants are more effective than placebo for LBP. [11] [12] [13] They have highlighted the need for high-quality trials and identified limitations of previous studies including insufficient blinding, small sample sizes, and short treatment and follow-up periods (≤3 months). Moreover, no studies have examined the effectiveness of a low-dose TCA, a common method of prescribing for LBP. Amitriptyline hydrochloride is a TCA widely used in low doses to treat pain, 6, 14 particularly nonspecific LBP, 3 independent of depression. 4 However, there is no evidence to support its widespread use. Thus, the aim of this double-blind, randomized clinical trial was to determine whether low-dose amitriptyline is effective in reducing pain, disability, and work absence and hindrance over 6 months in those with chronic, nonspecific LBP compared with an active comparator.
Methods
This study is a double-blind, randomized clinical trial, with a 2-arm, parallel-group, superiority design. The trial was registered at the Australian New Zealand Clinical Trials Registry (ACTRN12612000131853) prior to recruitment. Ethics approval was obtained from the Alfred Hospital Ethics Committee (HREC /12/Alfred/16:476/11), Monash University Human Research Ethics Committee (CF12/0271-2012000106), and Eastern Health Human Ethics Committee (SERP28/1112). Trial reporting was guided by the CONSORT guidelines. 15 The study protocol has been published 16 and is available in Supplement 1.
Sample
A total of 146 individuals with chronic LBP were recruited through hospital, medical, and allied health clinics and advertising in local media. Written informed consent was obtained prior to study commencement. We recruited men and women aged 18 to 75 years with chronic, nonspecific LBP, defined as pain below the costal margin and above the gluteal folds, without a specific cause and which had been present for greater than 3 months. 17 Participants with any of the following were excluded: pathological entity, major coexisting illness that might confound function or for which amitriptyline may be contraindicated, another significant musculoskeletal condition, history of psychosis, current or previously diagnosed depression with or without the use of medication, prior or current use of antidepressants, current use of opioids, any contraindication or allergy to amitriptyline, pregnancy, planning or trying to become pregnant or breastfeeding, or inability to give informed consent.
Randomization and Blinding
Randomization was based on computer-generated random numbers prepared by a statistician who had no involvement in trial conduct. Participants were allocated in a ratio of 1:1 to either the intervention or active comparator group. Although it was planned that block randomization based on hospital site would be used to stratify, most participants were recruited through advertising so this was not required. The use of a central allocation that involved pharmacy-controlled randomization ensured that the allocation could not be accessed by research personnel. Allocation concealment and double blinding was ensured by the following means: dispensing of medications by the hospital clinical trial pharmacy, use of an identical comparator tablet that mimicked the adverse events of amitriptyline, and questionnaire data that was collected by research assistants blinded to group allocation.
Study Intervention
Participants in the intervention arm received a low-dose TCA, 25 mg of amitriptyline (Alphapharm Pty Ltd), and those in the control arm received an active comparator, 1 mg benztropine mesylate (Phebra Pty Ltd). These were administered in identical capsules to be taken in a single dose at the same time each day for 6 months. We selected benztropine, an active comparator because it mimics adverse events of amitriptyline while having no known effect on chronic pain. 18, 19 Cost of medication was funded by the
Key Points
Question Is a low-dose tricyclic antidepressant effective in the treatment of chronic low back pain?
Findings In this randomized clinical trial of 146 participants with chronic low back pain, the use of low-dose amitriptyline did not demonstrate an improvement in pain, disability, or work at 6 months compared with an active comparator. However, there was a reduction in disability at 3 months, an improvement in pain intensity that was nonsignificant at 6 months, and minimal adverse events reported for the treatment group.
Meaning These results suggest that low-dose amitriptyline may be an effective treatment for chronic low back pain; although large-scale trials are needed, it may be worth considering amitriptyline, especially if the alternative is opioids. study, with no sponsorship from industry. All participants were provided with usual care by their treating practitioners, and the use of nonopioid analgesics and nonsteroidal antiinflammatory agents was allowed.
Study Procedure
Potential participants were telephone screened using a questionnaire to determine their eligibility. They then attended the study center for an assessment to confirm eligibility and obtain informed consent. Eligible participants were randomized, completed a baseline assessment, and received the first 3 months of amitriptyline or comparator from the Alfred Hospital Clinical Trials Pharmacy. Participants were contacted by telephone at 2 weeks, 1 to 2 months, 3 months, 4 to 5 months, and 6 months to monitor their progress and any adverse events. The 3-and 6-month outcome questionnaires and the second 3 months of medication were sent to the participants by mail. The same researchers, blinded to treatment allocation, administered questionnaires, monitored adherence, and recorded adverse events. Participants' adherence to trial medication was defined as the return of empty medication bottles at 6 months. Participants were not paid for their participation but were reimbursed for parking and transport costs.
Outcome Measures
Outcome measures were administered by research assistants blinded to group allocation at baseline and 3 and 6 months. The primary outcome measure was current level of pain intensity measured at 6 months using a 100-mm visual analog scale (VAS). The Descriptor Differential Scale (DDS; range, 0-20), a valid measure of pain intensity, 20 was also assessed because it has been used in a previous LBP trial of antidepressants.
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The secondary outcome of disability was assessed using the Roland Morris Disability Questionnaire (RMDQ), 22 a validated instrument designed to assess self-rated low back disability. Greater levels of disability are reflected by higher numbers, and scores are sensitive to change over time. 23 We examined absenteeism and hindrance in performance of paid and unpaid work using the Short Form Health and Labour Questionnaire, a validated questionnaire for examining work outcomes in relation to injury. 24 
Additional Outcomes
Global improvement was measured using a 6-point Likert scale (range, "much worse" to "completely recovered"). 25 General health status, depression, and fear of movement and/or (re)injury were measured using the EuroQol Instrument (version, EQ-5D-5L), 26 Beck Depression Inventory, 27 and Tampa scale, 28 respectively.
Other Measures
Height, weight, and body mass index (calculated as weight in kilograms divided by height in meters squared) were measured at baseline. We recorded any associated compensation claims and the nature of these claims. The presence of neuropathic pain was assessed using the painDetect questionnaire, with scores of 19 or greater reflecting a neuropathic component. 29 Adverse events were assessed using the UKU Side-Effects Rating Scale, 30 a validated questionnaire for assessing the severity and impact of adverse events on daily function due to psychotropic medication. Adverse events were examined at baseline, 2 weeks, and 2, 4, and 6 months. Adverse events were assessed according to their psychotropic, neurological, autonomic, or "other" nature and were recorded as mild, moderate, or severe. Details of major adverse events were reported to the ethics committees.
Sample Size Calculation
We determined that 150 patients (75 per group) would be needed to provide the trial with 90% power to detect a minimal clinically important difference (MCID) in pain intensity (15 points on 100-mm VAS 25, 31 ) and disability (3 points on ) between the groups at 6 months. This was assuming a 2-sided α level of .05 and mean (SD) for pain and disability of 2.5 (5) points and a maximum 20% withdrawal rate.
Statistical Analysis
Analyses were based on intention to treat. Summary statistics comparing randomized arms at baseline were tabulated. Continuous outcomes were analyzed using analysis of covariance, and logistic regression was performed for binary outcomes, with adjustments for baseline measurements where appropriate. Multiple imputation by chained equations 33 was used to impute missing 3-and 6-month pain, disability, and work data by treatment arm. A responder analysis was conducted in accordance with the National Institutes of Health Task Force Research Standards, 34 using the MCIDs for pain 25, 31 and disability 32 (as described herein)
to define a responder, and logistic regression for the analysis. The percentages of individuals with moderate or severe adverse events were calculated based on treatment, and differences between groups at baseline and 6 months, and over the 6-month period, were tested using χ 2 tests and generalized estimating equations for repeated measures, respectively. SPSS Statistics, version 22.0 (IBM Corp), was used and P < .05 was considered significant.
Results
From April 30, 2012, until June 1, 2016, 876 participants were screened and 146 randomized, with 72 allocated to the low-dose amitriptyline group and 74 to the active comparator group (Figure 1 ). The mean (SD) age of participants was 54.8 (13.7) years, mean (SD) body mass index was 29.4 (5.8), and 90 (62%) were men. Participants had a mean (SD) pain score of 41.6 (20.8) and disability score of 7.9 (4.5). A total of 35 (25%) and 117 (85%) participants reported work absence and hindrance owing to LBP, respectively. Baseline characteristics of participants are presented in Table 1 . Outcomes at 6 months were completed by 118 (81%) participants. Although the number of participants who did not complete the 6-month outcomes was small, we found no significant differences between participants who completed them and those who did not (eTable 1 in Supplement 2). A total of 53 (71%) participants in the active comparator group and 50 (70%) in the treatment group were found to be adherent to the study treatment. Table 2 presents the results for the primary and secondary outcomes. Although the low-dose amitriptyline group reported an adjusted mean (SE) reduction in pain intensity of 12.6 (2.7) points on the VAS from baseline to 6 months compared with a 4.8 (2.9)-point reduction for the active comparator group, treatment with low-dose amitriptyline did not result in a greater pain reduction at 6 months (adjusted difference, −7.81; 95% CI, −15.7 to 0.10) or 3 months (adjusted difference, −1.05; 95% CI, −7.87 to 5.78) (Figure 2 ). When multiple imputation was performed, the effect of low-dose amitriptyline on pain at 6 months was not significant (adjusted difference, −6.70; 95% CI, −14.4 to 1.04). There was no statistically significant difference in disability between groups at 6 months (adjusted difference, −0.98; 95% CI, −2.42 to 0.46); however, there was a statistically significant improvement in disability for the low-dose amitriptyline group at 3 months (adjusted difference, −1.62; 95% CI, −2.88 to −0.36) (Figure 2 ). There were no significant differences between groups in work absence (odds ratio [OR], 1.51; 95% CI, 0.43-5.38) or hindrance (OR, 0.53; 95% CI, 0.19-1.51) at 6 months. Moreover, responder analyses did not show clinically meaningful differences in pain or disability between the treatment groups (eTable 2 in Supplement 2). Table 3 presents data for additional outcomes. At 6 months, there were no significant differences in global improvement (adjusted difference, 0.08; 95% CI, −0.77 to 0.92), depression (adjusted difference, −0.93; 95% CI, −3.34 to 1.49), general health (adjusted difference, 5.01; 95% CI, −0.44 to 10.5), or fear of movement/reinjury (adjusted difference, −2.32; 95% CI, −4.91 to 0.26) in the treatment group compared with the active comparator group.
Nine (12%) participants from each group withdrew from the trial owing to adverse effects (χ 2 = 0.004; P = .95). There were no significant differences between the groups in the percentage of participants reporting moderate to severe symptoms at baseline (35% intervention, 41% comparator: χ 2 =0.63;P = .43) or 6 months (26% intervention, 32% comparator; χ 2 = 0.32; P = .58) (eTable 3inSupplement 2). Although the number of individuals who experienced moderate to severe symptoms appeared to be lower at 6 months than at baseline, this was not statistically significant for the intervention (35% baseline, 26% 6 months; P = .37) or comparator groups (41% baseline, 32% 6 months; P = .32). While a similar number of participants in both groups reported an increase in sleep duration at baseline (8% intervention, 12% comparator, χ 2 = 3.14; P = .37), more participants in the treatment group reported an increase in duration of sleep than those in the comparator group at 6 months (55% intervention, 16% comparator, χ 2 = 15.4; P < .001).
Discussion
To our knowledge, this is the first double-blind, randomized, controlled trial to examine the efficacy of a low-dose TCA for the treatment of chronic, nonspecific LBP. Although there were no significant differences in pain, disability, and work outcomes between the groups at 6 months, there was an improvement in disability at 3 months and minimal adverse events reported at 6 months for those treated with low-dose amitriptyline compared with the active comparator group. Although the improvements in pain intensity, general health and fear of movement/reinjury at 6 months did not reach statistical significance, they suggest that low-dose amitriptytline may have an effect with a larger sample size. These findings provide support for large-scale clinical trials, with an escalating dose as required, to determine the treatment effectiveness of amitriptyline. Previous systematic reviews, which have concluded that there is no clear evidence that antidepressants are effective for LBP, have identified major limitations of previous studies and the need for high-quality trials. 7, [11] [12] [13] The present trial aimed to address these limitations, namely, the lack of investigation of low-dose antidepressants for pain, insufficient blinding and statistical power, and short treatment and follow-up periods. We conducted a double-blind, randomized controlled trial of a low-dose TCA and compared it with an active comparator, which mimicked the adverse effects of amitriptyline and optimized blinding. The present study was sufficiently powered to detect a clinically meaningful effect of low-dose amitriptyline on pain and disability, and our treatment and follow-up periods were extended beyond those of previous studies to 6 months. While we did not meet our primary end point of a reduction in pain at 6 months, treatment with low-dose amitriptyline resulted in statistically significant improvements in disability with minimal adverse events, providing evidence to suggest that amitriptyline may have a therapeutic effect for LBP. This finding is important given that LBP is the leading cause of disability globally, 1 effective treatments for LBP are limited, 2 and there is currently an epidemic of escalated usage of narcotics, with more than 50% of narcotic prescriptions issued to people with LBP. 35 Moreover, recent systematic reviews have reported drug alternatives, such as paracetamol, 36 opioid analgesics, 37 and gabapentinoids, 38 to be ineffective, leaving physicians looking for an effective alternative. Amitriptyline is commonly used for LBP, and its off-label prescription is rapidly increasing. 6, 14 Although TCAs are not recommended in 2016 to 2017 international guidelines, 9,10 the use of low-dose amitriptyline is an attractive option for physicians given its efficacy in other pain conditions, 39, 40 and to many patients, who prefer the use of medications that they believe are simple, costeffective, and prevent their condition from becoming worse. 41 Moreover, the cornerstone of LBP management is encouraging individuals to stay active and progressively increase their activity levels. 9, 10 Given that a variety of factors, including pain, disability, and fear, are key barriers to activity and that in this trial we found that low-dose amitriptyline treatment may address a number of these factors, it is possible that low-dose .20
Abbreviation: NA, not applicable.
a Means and standard errors reported at baseline, 3 months, and 6 months.
b Analysis of covariance, adjusted for the baseline score.
c Pain intensity was assessed using the 100-mm visual analog scale where participants were asked to rate their current pain, with 0 indicating no pain and 10 indicating the worst pain imaginable. The minimal clinically important difference was 15 points. Means and standard errors reported at baseline, 3, and 6 months.
d Disability was measured using the Roland Morris Disability Questionnaire, with scores ranging from 0 to 23 and higher scores indicating greater disability. The minimal clinically important difference (MCID) was 3 points.
e Assessed using the Short Form Health and Labour Questionnaire (SFHLQ). Participants answered yes or no to whether they were off work during the past month due to their health. These are presented as odds ratios (95% CIs) calculated using logistic regression, adjusted for the baseline score.
amitriptyline may serve as a valuable treatment for LBP. While large trials, which include dose escalation, are needed to clarify the effect of amitriptyline treatment, it may be worth considering in the management of chronic LBP, especially if the alternative is prescribing opioids. We found that amitriptyline, prescribed in a low dose, was well tolerated. There was a similar number of withdrawals due to adverse events for both groups, indicating that the adverse events associated with low-dose amitriptyline are no greater than those of an active comparator. Of note, we found that prior to study commencement more than 30% of participants in each group had moderate to severe symptoms that were similar to the adverse events associated with psychotropic medications. 30 Given that these could not be attributed to the study medications, it suggests that a large proportion of the symptoms reported by individuals with chronic LBP who are taking TCAs may not be related to their medication use. Because low-dose TCAs are commonly prescribed for other conditions, such as headache, 40 it is important for physicians to be aware of this potential issue. Furthermore, the high proportion of psychotropic symptoms reported highlights the poor health status associated with LBP and the need to consider these symptoms in the management of the condition. b Analysis of covariance, adjusted for the baseline score, with the exception of "global improvement," where no adjustment was made because improvement cannot be assessed at baseline.
c Global improvement was measured using a 6-point Likert scale, ranging from "much worse" to "completely recovered," with higher scores indicating greater improvement.
d General health status was assessed using the EuroQol-Visual Analog Scale component of the EuroQol Instrument, ranging from 0 being the worst health you can imagine and 100 being the best health.
e Depression was measured using the Beck Depression Inventory, with scores ranging from 0 to 63 and higher scores (29-63) indicating more severe depressive symptoms.
f Fear of movement/(re)injury were measured using Tampa scale. The total score ranged between 17 and 68, with a high value indicating a greater fear of movement. Low-dose amitriptyline Active comparator A, Low back pain intensity was measured using the 100-mm visual analog scale (greater pain intensity is indicated by higher numbers). B, Low back disability was assessed using the Roland Morris Disability Questionnaire (0-23 points; greater levels of disability are reflected by higher numbers). The number of randomized participants in each of the groups who contributed the data at each time point is shown at the bottom of the graphs. The P values, derived from the analysis of covariance, adjusted for baseline score, for the pain intensity and disability outcomes are also shown. Measurements were performed at baseline and 3 and 6 months. Error bars indicate standard error of the mean. excluded individuals with a known, pathoanatomical cause for their LBP, and did not include a subgroup of individuals with a diagnosis of depression who may have differed in their pain response to amitriptyline treatment. We used the VAS and DDS to assess pain and allow comparison with previous studies. Although our participants experienced difficulty completing the DDS, the VAS was completed without issue and provided sufficient data for analysis. We powered this trial to detect statistical and clinical significant differences in pain and disability based on previous LBP trials of antidepressants and evidence on MCIDs for these measures. However, we did not power the trial to detect differences in our work or additional outcomes and it is therefore possible that the trial was underpowered in relation to these. Our follow-up rate was 81%, which is considered acceptable for a study of short to intermediate time frame. 42 Although we randomized 146, rather than the prespecified 150, the precision of the estimates of treatment effect based on the 95% CIs did not include a clinically significant effect. In this study we used an active comparator, benztropine, to reduce the potential of unblinding due to dry mouth. While benztropine has the potential to improve LBP through its sedating effect, it is unlikely that this occurred because a greater number of participants in the treatment group reported an increased sleep duration at 6 months than those in the benztropine group.
Conclusions
The results of this trial suggest that the use of low-dose amitriptyline may be an effective treatment for chronic LBP. Although we did not find statistically significant reductions in outcomes at 6 months, the findings of a reduction in disability at 3 months, an improvement in pain intensity that was nonsignificant at 6 months, and minimal adverse events with a low-dose, modest sample size and active comparator, provide support for largescale clinical trials of low dose amitriptyline, with gradual dose escalation. In the meantime, it may be worth trying low-dose amitriptyline for these patients, especially if the only alternative is an opioid.
ARTICLE INFORMATION
Accepted for Publication: July 4, 2018. Chronic low back pain (LBP) is a major public health problem. Although antidepressants are commonly used to treat pain in this condition, their efficacy is unproven.
Our Cochrane systematic reviews concluded that there is no clear evidence that antidepressants are effective for LBP. However, they identified significant heterogeneity in the study populations, with most trials not distinguishing between those with and without neuropathic LBP.
Neuropathic LBP is common and a significant cause of disability. Although the efficacy of antidepressants for neuropathic LBP is unknown, there is preliminary evidence to suggest that they may be beneficial in this subgroup of LBP.
Aims
In community-based adults with chronic, neuropathic LBP, we aim to determine: 1. If low dose amitriptyline (tricyclic antidepressant) is more effective than placebo in the management of pain 2. If low dose amitriptyline is more effective than placebo in improving function and reducing absence from paid/unpaid work 3. The cost-effectiveness of low-dose amitriptyline compared to placebo Methods A double-blind, randomized, placebo-controlled trial with an economic evaluation. We will recruit 150 subjects with chronic, neuropathic LBP. Participants will receive low-dose amitriptyline or an active placebo for 6 months. Pain, function and absence from work will be assessed at baseline, 3 and 6 months using valid instruments. Our economic evaluation will determine and compare all back pain related costs of patients receiving antidepressants and placebo.
Implications
If antidepressants are found to be effective, it will provide high quality evidence for their use and cost-effectiveness, potentially enabling this treatment option to be considered by more individuals with neuropathic low back pain. If we do not find antidepressants to be effective, then our trial will provide strong evidence to significantly reduce the prescription rate and subsidisation of antidepressant therapy.
INTRODUCTION

Title
Is low dose amitriptyline more effective than placebo in the management of chronic, neuropathic low back pain? A double-blind, randomized, placebo-controlled trial with an economic evaluation.
Rationale
Chronic low back pain is a major, but poorly understood, public health problem. Low dose antidepressants, at a much lower dose than used for the treatment of depression, are commonly used to manage chronic low back pain. This is the case, even though the evidence for their efficacy is unproven.
While our recent Cochrane systematic review concluded that there is no documented benefit from the use of antidepressant therapy, it identified a number of limitations in the available data, including the heterogeneity of populations previously investigated, particularly in relation to whether neuropathic pain was present or not. Moreover, there is evidence that low dose tricyclic antidepressants are effective in the treatment of neuropathic pain, such as diabetic and postherpetic neuralgia.
Chronic, neuropathic low back pain is a common and a significant cause of disability and results in a huge socioeconomic burden. If the use of antidepressants can reduce pain and loss of productivity associated with chronic, neuropathic low back pain, this could significantly reduce the costs associated with this debilitating condition, reducing the need for ongoing treatment and surgery, as well resulting in greater improvements in quality of life. If antidepressants are not cost-effective then their prescription for neuropathic, low back pain should be ceased and not subsidized.
The proposed study represents a potentially cost effective and innovative approach to the management of chronic, neuropathic low back pain and lends itself to a feasible public health intervention if successful. This study supports the objectives of the "Bone and Joint Decade" and addresses a National Health Priority Area.
OBJECTIVES
Primary
To perform a double-blind, randomized, placebo-controlled trial to investigate whether low dose amitriptyline (a tricyclic antidepressant) is more effective than placebo in the management of pain in community-based adults with chronic, neuropathic low back pain.
Secondary
To investigate whether low dose amitriptyline is more effective than placebo in improving functional status and minimizing absence from paid/unpaid work in chronic, neuropathic low back pain.
STUDY DESIGN
Experimental Design
A pragmatic, double-blind, randomized, placebo-controlled trial with an economic evaluation. The study will be conducted with adherence to the CONSORT guidelines.
Subject Selection
Definition of Disease State
We will recruit patients with chronic, neuropathic low back pain, defined as:
• Low back pain: defined as pain localised below the scapulae and above the gluteal folds • Chronic pain: defined as pain that has been present for at least 3 months 7 . Back pain that requires specific interventions are likely to have been clarified by 3 months and self-limiting back pain will have resolved.
• Presence of neuropathic pain: There is currently no reliable gold standard for the diagnosis of neuropathic pain and there are inherent limitations with most diagnostic tests, such as magnetic resonance imaging and neurophysiological tests 39 . Current recommendations for the identification of neuropathic pain include a clinical examination and a screening tool 40 .
Clinical Examination
We will perform a series of clinical tests, involving a neurological examination (including reflexes and muscle power), neural tension test, and sensory tests. The neural tension test will involve a straight leg raising test, which has a pooled sensitivity estimated to be 91% 41 , and the sensory examination will follow the short-form protocol developed by the German Research Network on Neuropathic Pain, which includes a range of well established tests, such as thermal, mechanical and vibration threshold testing 42 . These will be performed by the study physician.
Screening Tool: painDETECT questionnaire
We will administer the painDETECT questionnaire, a simple, patient-based, easy-to-use screening questionnaire, which has been shown to be reliable and valid for the identification of neuropathic pain components in heterogeneous cohorts of low back pain patients 40 . The questionnaire has been validated in about 8,000 patients with low back pain, and reaches about 80% sensitivity and specificity. The results of the clinical examination and questionnaire will be recorded at baseline.
Source and Number
We will recruit patients from hospital departments and outpatient clinics and general practitioner and allied health clinics located in Melbourne.
Entrance Criteria
Aged 18-70 years. Occupational low back pain is a major economic burden in the working population in Australia. We aim to perform an economic analysis. However, individuals will be included in the trial whether they perform paid or unpaid work.
Exclusion criteria:
• Specific pathological entities, such as infection, metastasis, osteoporosis, fractures.
• Candidates for spinal surgery • Major co-existing illness which might confound assessment of function or for which • antidepressants may be inappropriate • Other significant musculoskeletal conditions (eg fibromyalgia)
• Patients with any diagnosed depression or any prior or current use of antidepressants • History of psychosis • Any contra-indication or allergy to antidepressant medication • Inability to provide informed consent
Study Medication
Participants in the intervention arm will receive the tricyclic antidepressant, amitriptyline (Alphapharm, NSW; low dose; 25mg), and those in the control arm will receive an active placebo, benztropine mesylate (Phebra, NSW; 1mg). Amitriptyline and benztropine will be administered in identical capsules to be taken in a single dose at the same time each day (9.00 pm).
Rationale for selecting the tricyclic antidepressant amytriptyline
Low dose amitriptyline is commonly prescribed in Australia for the management of chronic pain 34 . It has been shown to be an effective treatment for various pain conditions, including fibromyalgia 35 , ankylosing spondylitis 36 and headaches 37 , and can act on pain independent of depression 28 . It has been reported to be the most effective antidepressant for the treatment of neuropathic pain, such as diabetic neuropathy and neuralgia 31 . Amitriptyline blocks the reuptake of norepinephrine and serotonin, neurotransmitters known to inhibit the transmission of pain. It is generally well tolerated.
Rationale for selecting the Benztropine mesylate
We have selected benztropine, an active placebo, as it mimics the side effects of amitriptyline, such as dry mouth and constipation, while having no known effect on chronic pain. Given this trial involves blinding, the choice of placebo is critical. If the side effects of the drug are not mimicked by the placebo then there is potential for unblinding. Benzotropine produces more effective blinding than an inert placebo and has been used as an active placebo in previous trials of neuropathic pain 47, 48 .
Side Effects/ Adverse events
Low dose amitriptyline is commonly used in general practice to treat pain. Typically lower dosages, ranging from 10 to 50 mg daily, are used for pain modification. Based on previous studies, we would expect adverse-events to occur in our trial, but for these to be mild and generally not lead to withdrawal. Adverse events such as dry mouth, mild constipation and fatigue can occur.
Adverse experiences will be documented at each assessment point throughout the study. Any serious adverse experiences, that is an adverse experience which is incapacitating and prevents normal everyday activities and/or requires therapeutic intervention (i.e. use of a prescription drug or hospitalisation), will be reported to the appropriate human research ethics committee and the appropriate procedures conducted.
Length of treatment
The length of the trial will be 6 months. Participants will commence on the medication/placebo to test the therapeutic efficacy of amitriptyline and side-effects of the medication will be monitored throughout the trial. Given the longest trial of antidepressants in chronic low back pain has been 12 weeks, a trial of 6 months enables the efficacy of the treatment to be examined over a longer time period.
3.4
Study Procedure
Recruitment
Participants will be recruited from hospital departments and outpatient clinics and general practitioner and allied health clinics in Melbourne.
Participants will be identified by; (i) clinicians having contact with patients and (ii) hospital staff checking patient hospital and clinic lists. Patients lists will be checked both retrospectively and prospectively to identify relevant patients. The names of potential participants will then be provided to the research team.
Initial contact with participants will be made by either the treating clinician or research personnel involved with the trial; 1. The treating clinician, who has a clinician/patient relationship with the participant, will briefly introduce the trial to the patient and ask them if they would be interested in being contacted by research staff with further information. This will occur in the clinic setting. If participants indicate they are happy to be contacted further, research personnel will contact them to discuss the study by phone.
2. In the case where potential participants have been identified from patient lists, participants will be posted a letter introducing them to the study and asking whether they would be interested in being contacted further. The letter will include a section enabling participants to opt-out of being contacted further. Senior research personnel will then contact participants who chose to receive further information about the study by phone.
Baseline Assessment
Participants who agree to be part of the study and have signed the study consent form will be assessed at baseline by a blinded study physician. A study physician was selected as low dose antidepressants, such as amitriptyline, are commonly prescribed by physicians for the management of pain in Australia 20 . The physician will perform the clinical tests and administer the painDETECT questionnaire (as described in section 3.2.1).
Commencement of the trial
On entry to the trial participants will receive either amitriptyline or the placebo. The randomisation, dispensing and drug accountability (ie storage, returns and disposal) will be undertaken by the Clinical Trials Pharmacy Department of the Alfred Hospital. Participants will receive either amitriptyline or placebo for a 3 month period at their initial baseline assessment. The study physician will discuss the dosage, side-effects and use of other medications with the participant. The participant will also be provided information from the 'Consumer Medicines' Advice Information sheet on amitriptyline.
Monitoring
To monitor compliance and side effects, participants will be monitored at 2 weeks, 1-2 months, 3 months, 4-5 months and 6 months using a validated questionnaire, the UKU Side Effects Rating Scale. This questionnaire involves a standardized, physician-administered interview for assessing the severity and impact of side effects on daily function due to psychotropic drugs 52 . The participants' physician will also be notified of their inclusion in the trial.
Outcome measures
The following primary and secondary outcome measures will be measured by blinded research assistants at baseline and 3 and 6 months. These time periods allow for assessment at baseline, during the trial, and at the conclusion of the study.
Primary outcome measure: Pain intensity, measured on the Descriptor Differential Scale (DDS) 53 and a visual analogue scale of at least 100 mm. The DDS is a valid measure of pain. It has been used in previous trials of antidepressants in low back pain, enabling calculation of study sample size and comparison of results.
Secondary outcome measures:
• Functional status; Roland Morris Disability Questionnaire (RDQ; back pain specific scale) 54 • Absence from paid/unpaid work; Short Form Health and Labour Questionnaire (SHLQ) 55 Additional measures:
• Global improvement; 6-point scale, ranging from "much worse" to "completely recovered"
• General Health Status, measured using the EuroQuol Instrument (EuroQol) 56 • Severity of mood symptoms will be assessed using the Beck Depression Inventory (BDI) 57 • Psychosocial variables including fear of movement/(re)injury using the 17-item Tampa  scale   58 3.4.6 Other measures 1. Anthropometry: Includes height and weight measured at baseline and 6 months. 2. Analgesics: Participants will be asked to discontinue opioid analgesics. This is an exclusion criteria. However, participants will be allowed to continue non-opioid analgesia and non-steroid anti-inflammatory medication. Data on their usage will be collected. 3. Physical activity: Using International Physical Activity Questionnaire (IPAQ -short version) 61 4. Compensation status: For each individual, we will record whether their back pain is associated with a compensation claim, and if so, the nature of the claim ie type (ie WorkSafe, Transport Accident Commission), duration, items approved and associated costs.
EXPERIMENTAL CONTROL
Randomisation
Randomization will be performed by an independent body -the Clinical Trials Department of the Alfred Hospital. Allocation concealment will be ensured by the use of identical, active placebo, and the use of a central automated allocation procedure, with security in place to ensure allocation data cannot be accessed or influenced by any person. Block randomization based on clinical site of recruitment will be used to reduce the confounding effects of the site. Randomization will be stratified by age and compensation status since subjects aged 50 years or greater have the capacity to influence the primary outcome of return to work and compensation, which has previously been shown to have adverse effects on self-reported pain and disability, both before and after interventions 46 .
Blinding Procedure
Participants will be blinded to whether they are in the intervention or placebo group. Blinding will involve the use of an active placebo. The active placebo will mimic the side-effects of amitriptyline. The physicians undertaking the baseline assessment and monitoring the side-effects and the research assistants administering the outcomes measures will also be blinded to the group participants are allocated to.
STATISTICAL CONSIDERATIONS
Summary statistics comparing randomized arms at baseline will be tabulated. Intention to treat analyses of primary and secondary continuous outcomes will be performed by linear regression adjusting for the baseline of the outcome variable where relevant. Logistic regression will be performed for binary outcomes. Adjustment for imbalanced baseline factors, including the presence of symptoms other than neuropathic pain (eg reduced muscle power and reflexes), will be performed as supplementary analyses. Analyses of treatment efficacy will be done by censoring individuals at the time of any protocol deviation and developing a model for the probability of deviation, followed by weighted analyses using only the uncensored individuals where the weights are the inverse probability of censoring. This produces estimates of treatment effect as if there was full compliance with the protocol in this RCT and is far preferable to per-protocol analyses based on (unweighted) observed compliance 62 . This RCT is well-placed to model non-compliance with frequent monitoring for adverse events and resultant prognostic information.
Sample size for primary outcome measures
A. Reduction in pain intensity: In a recent study of patients with low back pain, similar to those to be recruited for the current study (pain of moderate intensity (Mean: 9.4 (4.0)), the control group (n=22) had a pain score that reduced to a mean (SD) = 6.2 (2.8) on the Descriptor Differential Scale following treatment, while the pain score of the treatment group (TCA) (n=19) reduced to a mean (SD) score = 4.5 (2.6) 43. With an =0.05 and n=60 in each arm of the study, we have 90% power to detect a difference of this size (1.7), which reflects clinically significant reductions in pain intensity from moderate to mild or from strong to moderate, which is a equivalent to a decrease of 2 units (17%) on the Descriptor Differential Scale (0-12 per descriptor) 63 .
B) Improvement in functional status, expressed on a back pain-specific scale: With 60 in each arm of the study, we will have 90% power to detect a clinically relevant difference in disability (improvement of 13-16% in disability or 3-4 points on the 24 point Roland Morris Disability Questionnaire after 26 weeks 64) ( =0.05, 2 sided significance), which corresponds to a significant improvement in key functional activities, including walking and dressing 65 .
More generally, with 60 per arm we have 90% power to detect a difference of 0.60 standard deviations. With our primarily analyses involving adjustment for the baseline value of the outcome, we will have greater than 90% power according to the size of the baseline-followup correlation. Given our previous experience in such studies we expect a maximum drop out rate of 20% so we will recruit a total of 150 (75 in each arm of the study).
ADMINISTRATIVE PROCEDURES
Amendments to the Protocol
All modifications of the study will be written and filed as amendments to this protocol, maintaining original section identification. Such modification(s) will be approved by the appropriate Ethics Committees (where applicable). Any modifications to the study will be applied for all subsequent patients.
Early Termination or Extension of the Study
This research project may be terminated early for such reasons as unacceptable side effects, drug shown not to be effective or the drug/treatment being shown to work and not need further testing. In this event the human research ethics committees involved with be notified and the appropriate procedures followed.
Drug Accountability, Drug Packaging and Labelling, Storage of Study Drugs
The randomisation, dispensing (packaging and labelling) and drug accountability (ie storage, returns and disposal) will be undertaken by the Clinical Trials Pharmacy Department of the Alfred Hospital. Please refer to Pharmacy Resources Agreement for further information.
Confidentiality/Publication of Study Results
Study results will be published in aggregate form so that no results pertaining to any individual can be identified.
Retention of Records
All records associated with this study will be kept for at least 15 years as specified in the guidelines (Monash University Faculty of Medicine, Nursing and Health Science -A Guide to Good Research Practice (2011).
Audits
The investigators and research staff will participate and assist any audit of the project.
ETHICAL PROCEDURES
Guidelines for Good Clinical Research Practice
This study will be performed in accordance with the Monash University Faculty of Medicine, Nursing and Health Science -A Guide to Good Research Practice (2011) and NHMRC National Statement on Ethical Conduct in Human Research (2007).
Precautionary Advice
Given amitriptyline could have effects which interfere with subjects' normal activities or procedures e.g. drowsiness affecting ability to drive or use machinery, the research staff/investigators will give precautionary advice to the participants.
Participant Information and Consent Form (PI&CF)
An individual Participant Information and Consent Form has been prepared. Research staff will ensure that the approved consent form is signed by each patient prior to entry into the study.
Each patient's signed consent form will be retained and for confidentiality purposes will not be removed from the Monash University Department of Epidemiology and Preventive Medicine.
Volunteers/patients will be advised that they are free to refuse to participate in, or to withdraw from the study at any time. The medical care provided will not be affected by agreement or refusal to participate in this study.
Ethics Committee
This protocol will be submitted to the appropriate Human Ethics and Research Committees and their approval obtained.
REVISED STUDY PROTOCOL
Date: Version 5 10th May 2012
Chronic low back pain (LBP) is a major public health problem. Although antidepressants are commonly used to treat pain in this condition, their efficacy is unproven. Of note, our Cochrane systematic reviews concluded that there is no clear evidence that antidepressants are effective for LBP.
Aims
In community-based adults with chronic LBP, we aim to determine: 1. If low dose amitriptyline (tricyclic antidepressant) is more effective than placebo in the management of pain 2. If low dose amitriptyline is more effective than placebo in improving function and reducing absence from paid/unpaid work 3. The cost-effectiveness of low-dose amitriptyline compared to placebo Methods A double-blind, randomized, placebo-controlled trial with an economic evaluation. We will recruit 150 subjects with chronic LBP. Participants will receive low-dose amitriptyline or an active placebo for 6 months. Pain, function and absence from work will be assessed at baseline, 3 and 6 months using valid instruments. Our economic evaluation will determine and compare all back pain related costs of patients receiving antidepressants and placebo.
Implications
If antidepressants are found to be effective, it will provide high quality evidence for their use and cost-effectiveness, potentially enabling this treatment option to be considered by more individuals with low back pain. If we do not find antidepressants to be effective, then our trial will provide strong evidence to significantly reduce the prescription rate and subsidisation of antidepressant therapy.
INTRODUCTION
1.1 Title Is low dose amitriptyline more effective than placebo in the management of chroniclow back pain? A double-blind, randomized, placebo-controlled trial with an economic evaluation.
1.2
Rationale Chronic low back pain is a major, but poorly understood, public health problem. Low dose antidepressants, at a much lower dose than used for the treatment of depression, are commonly used to manage chronic low back pain. This is the case, even though the evidence for their efficacy is unproven. While our recent Cochrane systematic review concluded that there is no documented benefit from the use of antidepressant therapy, it identified a number of limitations in the available data.
Chronic low back pain is a common and a significant cause of disability and results in a huge socioeconomic burden. If the use of antidepressants can reduce pain and loss of productivity associated with chronic low back pain, this could significantly reduce the costs associated with this debilitating condition, reducing the need for ongoing treatment and surgery, as well resulting in greater improvements in quality of life. If antidepressants are not cost-effective then their prescription for low back pain should be ceased and not subsidized.
The proposed study represents a potentially cost effective and innovative approach to the management of chronic low back pain and lends itself to a feasible public health intervention if successful. This study supports the objectives of the "Bone and Joint Decade" and addresses a National Health Priority Area.
OBJECTIVES
Primary
To perform a double-blind, randomized, placebo-controlled trial to investigate whether low dose amitriptyline (a tricyclic antidepressant) is more effective than placebo in the management of pain in community-based adults with chronic low back pain.
2.2
Secondary To investigate whether low dose amitriptyline is more effective than placebo in improving functional status and minimizing absence from paid/unpaid work in chronic low back pain.
STUDY DESIGN
3.1
Experimental Design A pragmatic, double-blind, randomized, placebo-controlled trial with an economic evaluation. The study will be conducted with adherence to the CONSORT guidelines.
Subject Selection
Definition of Disease State
We will recruit patients with chronic low back pain, defined as:
• Low back pain: defined as pain localised below the scapulae and above the gluteal folds
• Chronic pain: defined as pain that has been present for at least 3 months 7 .Back pain that requires specific interventions are likely to have been clarified by 3 months and self-limiting back pain will have resolved.
Clinical Examination
Screening Tool: painDETECT questionnaire
Source and Number
Entrance Criteria
Aged 18-75 years: Occupational low back pain is a major economic burden in the working population in Australia. We aim to perform an economic analysis. However, individuals will be included in the trial whether they perform paid or unpaid work.
Exclusion criteria:
Study Medication
Rationale for selecting the tricyclic antidepressant amytriptyline
Rationale for selecting the Benztropine mesylate
We have selected benztropine, an active placebo, as it mimics the side effects of amitriptyline, such as dry mouth and constipation, while having no known effect on chronic pain. Given this trial involves blinding, the choice of placebo is critical. If the side effects of the drug are not mimicked by the placebo then there is potential for unblinding. Benzotropine produces more effective blinding than an inert placebo and has been used as an active placebo in previous trials of low back pain 47, 48 .
Side Effects/ Adverse events
Length of treatment
The length of the trial will be 6 months. Participants will commence on the medication/placebo to test the therapeutic efficacy of amitriptyline and side-effects of the medication will be monitored throughout the trial. Given the longest trial of anti-depressants in chronic low back pain has been 12 weeks, a trial of 6 months enables the efficacy of the treatment to be examined over a longer time period.
Study Procedure
Recruitment
Participants will be recruited from hospital departments and outpatient clinics and general practitioner and allied health clinics in Melbourne. Study flyers will also be placed on noticeboards at hospitals, clinics, local gyms, pilates centres and community groups. Advertisements will be placed in newspapers, magazines, and university and hospital newsletters and on internet sites. Participants will be identified by; (i) clinicians having contact with patients and (ii) hospital staff checking patient hospital and clinic lists. Patients lists will be checked both retrospectively and prospectively to identify relevant patients. The names of potential participants will then be provided to the research team.
Initial contact with participants will be made using the following methods; 1. The treating clinician, who has a clinician/patient relationship with the participant, will briefly introduce the trial to the patient and ask them if they would be interested in further information regarding the study. If the patient is interested in learning more about the study the treating clinician or research staff will provide the patient with a study flyer with some brief information about the trial. This will occur in the clinic setting. If participants indicate they are happy to be contacted further, research personnel will contact them to discuss the study by phone.
2. In the case where potential participants have been identified from patient lists, participants will be posted a letter introducing them to the study and asking whether they would be interested in being contacted further. The letter will include a section enabling participants to opt-out of being contacted further. Senior research personnel will then contact participants who chose to receive further information about the study by phone. 3. Study flyers will also be placed on hospital and clinic noticeboards. Potential participants who read the flyer and are interested in learning more about the study will be able to contact research personnel. 4. Advertisements will be placed in newspapers, magazines, and university and hospital newsletters and on internet sites. Potential participants who read the advertisement and are interested in learning more about the study will be able to contact research personnel.
Baseline Assessment
Commencement of the trial
Monitoring
Outcome measures
Primary outcome measure: Pain intensity, measured on the Descriptor Differential Scale (DDS) 53 and a visual analogue scale of at least 20 mm. The DDS is a valid measure of pain. It has been used in previous trials of antidepressants in low back pain, enabling calculation of study sample size and comparison of results.
Secondary outcome measures:
• Functional status; Roland Morris Disability Questionnaire (RDQ; back pain specific scale) 54 • Absence from paid/unpaid work; Short Form Health and Labour Questionnaire (SHLQ) 55
5.1
Sample size for primary outcome measures A. Reduction in pain intensity: In a recent study of patients with low back pain, similar to those to be recruited for the current study (pain of moderate intensity (Mean: 9.4 (4.0)), the control group (n=22) had a pain score that reduced to a mean (SD) = 6.2 (2.8) on the Descriptor Differential Scale following treatment, while the pain score of the treatment group (TCA) (n=19) reduced to a mean (SD) score = 4.5 (2.6) 43. With an =0.05 and n=60 in each arm of the study, we have 90% power to detect a difference of this size (1.7), which reflects clinically significant reductions in pain intensity from moderate to mild or from strong to moderate, which is a equivalent to a decrease of 2 units (17%) on the Descriptor Differential Scale (0-12 per descriptor) 63 .
ADMINISTRATIVE PROCEDURES
6.1
Amendments to the Protocol All modifications of the study will be written and filed as amendments to this protocol, maintaining original section identification. Such modification(s) will be approved by the appropriate Ethics Committees (where applicable). Any modifications to the study will be applied for all subsequent patients.
6.2
Early Termination or Extension of the Study This research project may be terminated early for such reasons as unacceptable side effects, drug shown not to be effective or the drug/treatment being shown to work and not need further testing. In this event the human research ethics committees involved with be notified and the appropriate procedures followed.
6.3
Drug Accountability, Drug Packaging and Labelling, Storage of Study Drugs The randomisation, dispensing (packaging and labelling) and drug accountability (ie storage, returns and disposal) will be undertaken by the Clinical Trials Pharmacy Department of the Alfred Hospital. Please refer to Pharmacy Resources Agreement for further information.
6.4
Confidentiality/Publication of Study Results Study results will be published in aggregate form so that no results pertaining to any individual can be identified.
6.5
Retention of Records All records associated with this study will be kept for at least 15 years as specified in the guidelines (Monash University Faculty of Medicine, Nursing and Health Science -A Guide to Good Research Practice (2011).
6.6
Audits The investigators and research staff will participate and assist any audit of the project. 
ETHICAL PROCEDURES
Guidelines for Good Clinical Research Practice
7.2
Precautionary Advice Given amitriptyline could have effects which interfere with subjects' normal activities or procedures e.g. drowsiness affecting ability to drive or use machinery, the research staff/investigators will give precautionary advice to the participants.
7.3
Participant Information and Consent Form (PI&CF) An individual Participant Information and Consent Form has been prepared. Research staff will ensure that the approved consent form is signed by each patient prior to entry into the study. Each patient's signed consent form will be retained and for confidentiality purposes will not be removed from the Monash University Department of Epidemiology and Preventive Medicine.
7.4
Ethics Committee This protocol will be submitted to the appropriate Human Ethics and Research Committees and their approval obtained. Side-effects were assessed using the UKU Side-Effects Rating Scale as moderate/severe (yes/no) in the categories of psychic, neurological, autonomic, or 'other' Of the 13 and 15 participants that discontinued the trial from the treatment and comparator groups respectively, 9 from each group withdrew due to side-effects. 1 0 missing data points, 2 13 missing data points, 3 1 missing data point, 4 15 missing data points. 5 Statistical differences were examined using Chi-square tests.
